The same research team further demonstrated that the combination of cyst(e)inase, an engineered enzyme which degrades both cystine and cysteine, and ICB therapy synergistically impairs cystine uptake via xCT in tumor cells, resulting in GSH deficiency, ROS accumulation, lipid peroxidation, and ferroptosis of cancer cells in preclinical models [164]. The gene discussed is SLC7A11; the disease is neoplasm.